The biology of VEGF and its receptors
The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor (VEGF) is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and reproductive functions. VEGF has also been implicated in pathological angiogenesis associated with tumors, intraocular neovascular disorders and other conditions. The biological effects of VEGF are mediated by two receptor tyrosine kinases (RTKs), VEGFR-1 and VEGFR-2, which differ considerably in signaling properties. Non-signaling co-receptors also modulate VEGF RTK signaling. Currently, several VEGF inhibitors are undergoing clinical testing in several malignancies. VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is well established that the formation of blood vessels occurs by angiogenesis and that vascular endothelial growth factor (VEGF) is a key molecule in promoting angiogenesis (Ferrara et al., 2003).”
From Molecular pathology of age-related macular degeneration (2009) · cites this paper as Ferrara et al., 2003
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 1×
“VEGF induces a potent angiogenic response in a variety of in vivo model”
BackgroundSelf-citationThe Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Self-citationMechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972 · cited 1×
“VEGF is known also as vascular permeability factor, based on its ability to induce vascular leakag”
BackgroundFailure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Self-citationVascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“Many molecules have been implicated as positive regulators of angiogenesis, including acidic fibroblast growth factor (FGF), basic FGF, transforming growth factor (TGF)-α, TGF-β, hepatocyte growth factor (HGF, or scatter factor), tumor necrosis factor-α, angiogenin, interleukin (IL)-8 and the angiopoietin”
BackgroundHeterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,628 · cited 1×
“In 1996, two studies showed an essential role of VEGF in embryonic vasculogenesis and angiogenesi”
BackgroundSelf-citationKim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Self-citationVascular endothelial growth factor (VEGF) and its receptors
NEUFELD, G., COHEN, T., GENGRINOVITCH, S., & POLTORAK, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,483 · cited 1×
“Homologs of VEGF have also been identified in the genome of the parapoxvirus Orf virus and shown to have VEGF-like activitie”
BackgroundDvorak, H. F., Brown, L. F., Detmar, M. J., & Dvořàk, A. M. (1995) · Europe PMC (PubMed Central) · Cited by 3,115
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797 · cited 1×
“Furthermore, at least in this model, proteolytic events mediated by matrix metalloproteinase-9 result in enhancement of the activity of low, constitutive VEGF, by making it available to bind VEGFR-2 (ref”
BackgroundFolkman, J., & Shing, Y. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49853-0 · Cited by 2,654
Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
Fong, G.-H., Rossant, J., Gertsenstein, M., & Breitman, M. L. (1995) · Nature · doi:10.1038/376066a0 · Cited by 2,606
Soker, S., Takashima, S., Miao, H. Q., Neufeld, G., & Klagsbrun, M. (1998) · Cell · doi:10.1016/s0092-8674(00)81402-6 · Cited by 2,463
Ferrara, N., & Henzel, W. J. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92678-8 · Cited by 2,268 · cited 1×
“Native VEGF is a heparin-binding homodimeric glycoprotein of 45 kDa (ref”
BackgroundSelf-citationGerber, H.-P., Vu, T. H., Ryan, A. M., Kowalski, J., Werb, Z., & Ferrara, N. (1999) · Nature Medicine · doi:10.1038/9467 · Cited by 2,085
Self-citationHIF-1α is essential for myeloid cell-mediated inflammation
Cramer, T., Yamanishi, Y., Clausen, B. E., Förster, I., Pawlinski, R., Mackman, N., Haase, V. H., Jaenisch, R., Corr, M., Nizet, V., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00154-5 · Cited by 2,046
Self-citationThe fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor
de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., & Williams, L. T. (1992) · Science · doi:10.1126/science.1312256 · Cited by 2,016
Self-citationGerber, H.-P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30336 · Cited by 1,981
Self-citationGabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977 · cited 1×
“VEGF delivery to adult mice inhibits dendritic cell developmen”
BackgroundKabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716 · cited 1×
“Phase 2 clinical data have provided initial evidence that rhuMab VEGF, in combination with conventional chemotherapy, results in increase in time to progression and even survival in patients with metastatic colorectal carcinom”
BackgroundVEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., De Mol, M., Wu, Y., Bono, F., Devy, L., Beck, H., et al. (2001) · Nature Medicine · doi:10.1038/87904 · Cited by 1,672
Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M., & Heldin, C. H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47116-5 · Cited by 1,656
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Self-citationVEGF and the quest for tumour angiogenesis factors
Ferrara, N. (2002) · Nature Reviews Cancer · doi:10.1038/nrc909 · Cited by 1,536 · cited 1×
“For over a decade, the role of VEGF (also referred to as VEGFA) in the regulation of angiogenesis was the object of intense investigation (see ref”
BackgroundSelf-citationIdentification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
Terman, B. I., Dougher-Vermazen, M., Carrion, M. E., Dimitrov, D., Armellino, D. C., Gospodarowicz, D., & Böhlen, P. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)90483-2 · Cited by 1,519 · cited 1×
“VEGFR-2 binds VEGF with a K d of approximately 75–125 pM (ref”
BackgroundClinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517 · cited 1×
“Some evidence suggests that VEGF may be especially critical during the initial stage”
BackgroundTischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J. C., & Abraham, J. A. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99049-6 · Cited by 1,476
Street, J., Bao, M., deGuzman, L., Bunting, S., Peale, F. V., Ferrara, N., Steinmetz, H., Hoeffel, J., Cleland, J. L., Daugherty, A., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152324099 · Cited by 1,404 · cited 1×
“A recent study has shown that VEGF administration leads to enhanced blood vessel formation and ossification in models of bone damag”
BackgroundSelf-citationKendall, R. L., & Thomas, K. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10705 · Cited by 1,394 · cited 1×
“An alternatively spliced, soluble form of VEGFR-1 (soluble Flt-1) is an inhibitor of VEGF activit”
BackgroundHouck, K. A., Ferrara, N., Winer, J., Cachianes, G., Li, B., & Leung, D. W. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-12-1806 · Cited by 1,365 · cited 1×
“VEGF isoforms The human VEGFA gene is organized as eight exons separated by seven intron”
BackgroundSelf-citationBarleon, B., Sozzani, S., Zhou, D., Weich, H., Mantovani, A., & Marme, D. (1996) · Blood · doi:10.1182/blood.v87.8.3336.bloodjournal8783336 · Cited by 1,356
Eremina, V., Sood, M., Haigh, J., Nagy, A., Lajoie, G., Ferrara, N., Gerber, H.-P., Kikkawa, Y., Miner, J. H., & Quaggin, S. E. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17423 · Cited by 1,313
Self-citationAiello, L. P., Pierce, E. A., Foley, E. D., Takagi, H., Chen, H., Riddle, L., Ferrara, N., King, G. L., & Smith, L. E. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10457 · Cited by 1,260 · cited 1×
“Subsequent animal studies using various VEGF inhibitors have directly shown the role of VEGF as a mediator of ischemia-induced intraocular neovascularizatio”
Self-citationBenjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241 · cited 1×
“VEGF is a survival factor for ECs, both in vitro and in vivo”
BackgroundKlement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Houck, K. A., Leung, D. W., Rowland, A. M., Winer, J., & Ferrara, N. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35712-0 · Cited by 1,127
Self-citationPark, J. E., Keller, G. A., & Ferrara, N. (1993) · Molecular Biology of the Cell · doi:10.1091/mbc.4.12.1317 · Cited by 1,122
Self-citationPark, J. E., Chen, H. H., Winer, J., Houck, K. A., & Ferrara, N. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47298-5 · Cited by 1,112
Self-citationLuttun, A., Tjwa, M., Moons, L., Wu, Y., Angelillo-Scherrer, A., Liao, F., Nagy, J. A., Hooper, A., Priller, J., De Klerck, B., et al. (2002) · Nature Medicine · doi:10.1038/nm731 · Cited by 1,068
Hiratsuka, S., Minowa, O., Kuno, J., Noda, T., & Shibuya, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9349 · Cited by 1,062 · cited 1×
“Support for this view also stems from the report that a targeted mutation resulting in a VEGFR-1 lacking the tyrosine kinase domain, but still able to bind VEGF, does not result in lethality or any overt defect in vascular developmen”
BackgroundRoberts, W. G., & Palade, G. E. (1995) · Journal of Cell Science · doi:10.1242/jcs.108.6.2369 · Cited by 1,033
The VIVA Trial: Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis
Henry, T. D., Annex, B. H., McKendall, G. R., Azrin, M. A., Lopez, J. J., Giordano, F. J., Shah, P. K., Willerson, J. T., Benza, R. L., Berman, D. S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000061911.47710.8a · Cited by 1,025 · cited 1×
“Thus far, clinical results with VEGF (or basic FGF) have been somewhat disappointing because the treatment did not significantly increase exercise treadmill time, although some improvement in angina class was measured in a placebo-controlled trial with recombinant VEGF 165 in coronary ischemia patient”
ResultClinical applications of angiogenic growth factors and their inhibitors
Ferrara, N., & Alitalo, K. (1999) · Nature Medicine · doi:10.1038/70928 · Cited by 1,004
Self-citationTumor Induction of VEGF Promoter Activity in Stromal Cells
Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996
Gerber, H.-P., Dixit, V., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.21.13313 · Cited by 981 · cited 1×
“VEGF is a survival factor for ECs, both in vitro and in vivo”
BackgroundSelf-citationShibuya, M., Yamaguchi, S., Yamane, A., Ikeda, T., Tojo, A., Matsushime, H., & Sato, M. (1990) · PubMed · Cited by 960
VEGF is required for growth and survival in neonatal mice
Gerber, H.-P., Hillan, K. J., Ryan, A. M., Kowalski, J., Keller, G.-A., Rangell, L., Wright, B. D., Radtke, F., Aguet, M., & Ferrara, N. (1999) · Development · doi:10.1242/dev.126.6.1149 · Cited by 915
Self-citationRuhrberg, C., Gerhardt, H., Golding, M., Watson, R., Ioannidou, S., Fujisawa, H., Betsholtz, C., & Shima, D. T. (2002) · Genes & Development · doi:10.1101/gad.242002 · Cited by 914
Hiratsuka, S., Nakamura, K., Iwai, S., Murakami, M., Itoh, T., Kijima, H., Shipley, J. M., Senior, R. M., & Shibuya, M. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00153-8 · Cited by 910
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G., & Goldberg, M. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10595 · Cited by 892
Signal transduction to hypoxia-inducible factor 1
Semenza, G. L. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01168-1 · Cited by 860 · cited 1×
“It is now well established that hypoxia-inducible factor (HIF)-1 is a key mediator of hypoxic response”
BackgroundWood, J. M., Bold, G., Buchdunger, E., Cozens, R. M., Ferrari, S. M., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., et al. (2000) · PubMed · Cited by 845
Clauss, M., Gerlach, M., Gerlach, H., Brett, J., Wang, F., Familletti, P. C., Pan, Y. C., Olander, J. V., Connolly, D. T., & Stern, D. (1990) · The Journal of experimental medicine · doi:10.1084/jem.172.6.1535 · Cited by 835
A requirement for neuropilin-1 in embryonic vessel formation
Kawasaki, T., Kitsukawa, T., Bekku, Y., Matsuda, Y., Sanbo, M., Yagi, T., & Fujisawa, H. (1999) · Development · doi:10.1242/dev.126.21.4895 · Cited by 827
Selective Requirement for Src Kinases during VEGF-Induced Angiogenesis and Vascular Permeability
Eliceiri, B. P., Paul, R., Schwartzberg, P. L., Hood, J. D., Leng, J., & Cheresh, D. A. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80221-x · Cited by 813
Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes
Gerber, H.-P., Condorelli, F., Park, J., & Ferrara, N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.38.23659 · Cited by 794
Self-citationRuckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L., & Janjic, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 744 · cited 1×
“or 2′-fluoropyrimidine RNA oligonucleotide ligand (aptamer”
Lee, C. G., Heijn, M., di Tomaso, E., Griffon, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., et al. (2000) · PubMed · Cited by 733
Self-citationCompernolle, V., Brusselmans, K., Acker, T., Hoet, P., Tjwa, M., Beck, H., Plaisance, S., Dor, Y., Keshet, E., Lupu, F., et al. (2002) · Nature Medicine · doi:10.1038/nm721 · Cited by 732 · cited 1×
“Recent studies have also shown that VEGF stimulates surfactant production by alveolar type II cell”
ResultYuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., & Jain, R. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14765 · Cited by 719 · cited 1×
“VEGF is a survival factor for ECs, both in vitro and in vivo”
BackgroundSelf-citationPrewett, M. C., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K. D., Overholser, J. C., Hooper, A. T., Pytowski, B., Witte, L., et al. (1999) · PubMed · Cited by 713
VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism
Gerber, H.-P., Malik, A. K., Solar, G. P., Sherman, D., Liang, X. H., Meng, G., Hong, K., Marsters, J. C., & Ferrara, N. (2002) · Nature · doi:10.1038/nature00821 · Cited by 706
Self-citationHattori, K., Dias, S., Heissig, B., Hackett, N. R., Lyden, D., Tateno, M., Hicklin, D. J., Zhu, Z., Witte, L., Crystal, R. G., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.9.1005 · Cited by 687 · cited 1×
“and increases production of B cells and generation of immature myeloid cell”
BackgroundAngiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1
LeCouter, J., Moritz, D. R., Li, B., Phillips, G. L., Liang, X. H., Gerber, H.-P., Hillan, K. J., & Ferrara, N. (2003) · Science · doi:10.1126/science.1079562 · Cited by 679 · cited 1×
“VEGFR-1 activation resulted in the paracrine release of HGF, IL-6 and other hepatotrophic molecules by LSECs, such that hepatocytes were stimulated to proliferate when cultured with LSEC”
BackgroundSelf-citationCarmeliet, P., Ng, Y.-S., Nuyens, D., Theilmeier, G., Brusselmans, K., Cornelissen, I., Ehler, E., Kakkar, V. V., Stalmans, I., Mattot, V., et al. (1999) · Nature Medicine · doi:10.1038/8379 · Cited by 679
Identification of a new endothelial cell growth factor receptor tyrosine kinase.
Terman, B. I., Carrion, M. E., Kovacs, E., Rasmussen, B. A., Eddy, R. L., & Shows, T. B. (1991) · Oncogene · Cited by 641
Adamis, A. P. (1996) · Archives of Ophthalmology · doi:10.1001/archopht.1996.01100130062010 · Cited by 635
Hattori, K., Heissig, B., Wu, Y., Dias, S., Tejada, R., Ferris, B., Hicklin, D. J., Zhu, Z., Bohlen, P., Witte, L., et al. (2002) · Nature Medicine · doi:10.1038/nm740 · Cited by 633 · cited 1×
“VEGFR-1 activation by PLGF is able to reconstitute hematopoiesis by recruiting VEGFR-1-positive HSC”
BackgroundVascular endothelial growth factor is essential for corpus luteum angiogenesis
Ferrara, N., Chen, H., Davis-Smyth, T., Gerber, H.-P., Nguyen, T.-N., Peers, D., Chisholm, V., Hillan, K. J., & Schwall, R. H. (1998) · Nature Medicine · doi:10.1038/nm0398-336 · Cited by 624 · cited 1×
“Administration of VEGF inhibitors suppresses luteal angiogenesi”
Self-citationAnalysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2)
Gille, H., Kowalski, J., Li, B., LeCouter, J., Moffat, B., Zioncheck, T. F., Pelletier, N., & Ferrara, N. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m002016200 · Cited by 620
Self-citationKeyt, B. A., Berleau, L. T., Nguyen, H. V., Chen, H., Heinsohn, H., Vandlen, R., & Ferrara, N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.13.7788 · Cited by 604
Self-citationLopez, P. F., Sippy, B. D., Lambert, H. M., Thach, A. B., & Hinton, D. R. (1998) · Retina · doi:10.1097/00006982-199805000-00035 · Cited by 592
Krzystolik, M. G. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.3.338 · Cited by 590 · cited 1×
“Treatment with rhuFab VEGF reduces angiogenesis and vascular leakage in a primate model of AM”
BackgroundTakahashi, T., Ueno, H., & Shibuya, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202527 · Cited by 571
Olofsson, B., Korpelainen, E., Pepper, M. S., Mandriota, S. J., Aase, K., Kumar, V., Gunji, Y., Jeltsch, M. M., Shibuya, M., Alitalo, K., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11709 · Cited by 560
Nagy, J. A., Vasile, E., Feng, D., Sundberg, C., Brown, L. F., Detmar, M. J., Lawitts, J. A., Benjamin, L., Tan, X., Manseau, E. J., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021244 · Cited by 559 · cited 1×
“VEGF delivery also induces lymphangiogenesis in mic”
Identification of an angiogenic mitogen selective for endocrine gland endothelium
LeCouter, J., Kowalski, J., Foster, J., Hass, P., Zhang, Z., Dillard-Telm, L., Frantz, G., Rangell, L., DeGuzman, L., Keller, G.-A., et al. (2001) · Nature · doi:10.1038/35091000 · Cited by 555
Self-citationDetmar, M., Brown, L. F., Schön, M. P., Elicker, B. M., Velasco, P., Richard, L., Fukumura, D., Monsky, W., Claffey, K. P., & Jain, R. K. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00262.x · Cited by 550
VEGF Receptor Signal Transduction
Matsumoto, T., & Claesson-Welsh, L. (2001) · Science's STKE · doi:10.1126/stke.2001.112.re21 · Cited by 502
McLaren, J., Prentice, A., Charnock-Jones, D. S., Millican, S. A., Müller, K. H., Sharkey, A. M., & Smith, S. K. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118815 · Cited by 500 · cited 1×
“Large amounts of VEGF have been measured in the peritoneal fluid of patients with endometriosi”
BackgroundPlouët, J., Schilling, J., & Gospodarowicz, D. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb08557.x · Cited by 492
Guo, D., Jia, Q., Song, H.-Y., Warren, R. S., & Donner, D. B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.12.6729 · Cited by 482
Aliello, L. P. (1995) · Medical Entomology and Zoology · Cited by 463
Fong, G.-H., Zhang, L., Bryce, D.-M., & Peng, J. (1999) · Development · doi:10.1242/dev.126.13.3015 · Cited by 459
van Bruggen, N., Thibodeaux, H., Palmer, J. T., Lee, W. P., Fu, L., Cairns, B., Tumas, D., Gerlai, R., Williams, S.-P., Campagne, M. V. L., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8218 · Cited by 457
Self-citationChen, Y., Wiesmann, C., Fuh, G., Li, B., Christinger, H. W., McKay, P., de Vos, A. M., & Lowman, H. B. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3192 · Cited by 448 · cited 1×
“Currently, anti-VEGF strategies are being explored in clinical trials in AMD patients, using either a recombinant humanized VEGF-specific Fab (rhuFab VEGF”
BackgroundVascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries
Ku, D. D., Zaleski, J. K., Liu, S., & Brock, T. A. (1993) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1993.265.2.h586 · Cited by 445
Skeletal defects in VEGF120/120 mice reveal multiple roles for VEGF in skeletogenesis
Zelzer, E., McLean, W., Ng, Y.-S., Fukai, N., Reginato, A. M., Lovejoy, S., D’Amore, P. A., & Olsen, B. R. (2002) · Development · doi:10.1242/dev.129.8.1893 · Cited by 445
Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
Dias, S., Hattori, K., Zhu, Z., Heissig, B., Choy, M., Lane, W., Wu, Y., Chadburn, A., Hyjek, E., Gill, M., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8978 · Cited by 434 · cited 1×
“In addition, an antibody to VEGFR-2 inhibits proliferation of xenotransplanted human leukemia cells and increases survival of nude mic”
BackgroundDor, Y. (2002) · The EMBO Journal · doi:10.1093/emboj/21.8.1939 · Cited by 390 · cited 1×
“A critical duration of exposure, however, resulted in persistence of vessels for months after VEGF withdrawal, and improved organ perfusio”
BackgroundInoue, M., Hager, J. H., Ferrara, N., Gerber, H.-P., & Hanahan, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00031-4 · Cited by 380 · cited 1×
“Cre- lox P–mediated gene targeting has been used to show that VEGF inactivation suppresses tumour angiogenesis in the Rip-Tag model, a well-established genetic model of insulinom”
MethodSelf-citationMäkinen, K., Manninen, H., Hedman, M., Matsi, P., Mussalo, H., Alhava, E., & Ylä-Herttuala, S. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0638 · Cited by 374 · cited 1×
“An increase in vascularity was reported in a controlled trial with adenovirus-mediated delivery of VEGF 165 in limb ischemia patient”
BackgroundHIF hydroxylation and the mammalian oxygen-sensing pathway
Safran, M., & Kaelin, W. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318181 · Cited by 365
Malecaze, F. (1994) · Archives of Ophthalmology · doi:10.1001/archopht.1994.01090230090028 · Cited by 364
HIF hydroxylation and the mammalian oxygen-sensing pathway
Safran, M., & Kaelin, W. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18181 · Cited by 363 · cited 1×
“Recently, a family of prolyl hydroxylases related to the Caenorhabditis elegans Egl-9 gene product was identified as the HIF prolyl hydroxylase”
BackgroundNeufeld, G. (2002) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(01)00140-2 · Cited by 350
Soker, S., Fidder, H., Neufeld, G., & Klagsbrun, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.10.5761 · Cited by 343
Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke
Paul, R., Zhang, Z. G., Eliceiri, B. P., Jiang, Q., Boccia, A. D., Zhang, R. L., Chopp, M., & Cheresh, D. A. (2001) · Nature Medicine · doi:10.1038/84675 · Cited by 342
Bellomo, D., Headrick, J. P., Silins, G. U., Paterson, C. A., Thomas, P. S., Gartside, M., Mould, A., Cahill, M. M., Tonks, I. D., Grimmond, S. M., et al. (2000) · Circulation Research · doi:10.1161/01.res.86.2.e29 · Cited by 333
Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B., & Marmé, D. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25915 · Cited by 329 · cited 1×
“Oncogenic mutations or amplification of Ras lead to VEGF upregulatio”
BackgroundOxygen sensors and angiogenesis
Maxwell, P. H., & Ratcliffe, P. J. (2002) · Seminars in Cell & Developmental Biology · doi:10.1006/scdb.2001.0287 · Cited by 329 · cited 1×
“Other studies showed that VHL is part of a ubiquitin-ligase complex that targets HIF-1 subunits for proteasomal degradation after covalent attachment of a polyubiquitin chain (reviewed in ref”
BackgroundSiemeister, G., Weindel, K., Mohrs, K., Barleon, B., Martiny‐Baron, G., & Marmé, D. (1996) · PubMed · Cited by 308
Tsuzuki, Y., Fukumura, D., Oosthuyse, B., Koike, C., Carmeliet, P., & Jain, R. K. (2000) · PubMed · Cited by 301
Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis.
Goede, V., Schmidt, T., Kimmina, S., Kozian, D. H., & Augustin, H. G. (1998) · PubMed · Cited by 299
Kitamoto, Y., Tokunaga, H., & Tomita, K. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119416 · Cited by 294 · cited 1×
“Defective glomerular development in neonates was also observed in studies using antibodies to VEG”
ResultVascular Endothelial Growth Factor is Expressed in Rat Corpus Luteum
PHILLIPS, H. S., HAINS, J., LEUNG, D. W., & FERRARA, N. (1990) · Endocrinology · doi:10.1210/endo-127-2-965 · Cited by 277 · cited 1×
“Previous studies have shown that VEGF mRNA expression is temporally and spatially related to the proliferation of blood vessels in the ovar”
BackgroundSelf-citationVEGF and flt: Expression Time Kinetics in Rat Brain Infarct
Kovács, Z., Ikezaki, K., Samoto, K., Inamura, T., & Fukui, M. (1996) · Stroke · doi:10.1161/01.str.27.10.1865 · Cited by 277
Okada, F., Rak, J. W., Croix, B. S., Lieubeau, B., Kaya, M., Roncari, L., Shirasawa, S., Sasazuki, T., & Kerbel, R. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3609 · Cited by 267
Persico, M. G. (2001) · Vascular Morphogenesis in the Female Reproductive System · doi:10.1007/978-1-4612-0213-4_16 · Cited by 259
Hall, B. K., & Newman, S. A. (1991) · Medical Entomology and Zoology · Cited by 259
Gerber, H., Kowalski, J., Sherman, D. A., Eberhard, D. A., & Ferrara, N. (2000) · PubMed · Cited by 251
Self-citationEffects of Vascular Endothelial Growth Factor on Hemodynamics and Cardiac Performance
Yang, R., Thomas, G. R., Bunting, S., Ko, A., Ferrara, N., Keyt, B., Ross, J., & Jin, H. (1996) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199606000-00011 · Cited by 244
Self-citationDetmar, M., Yeo, K.-T., Nagy, J. A., van de Water, L., Brown, L. F., Berse, B., Elicker, B. M., Ledbetter, S., & Dvorak, H. F. (1995) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12312542 · Cited by 242 · cited 1×
“VEGF is strongly expressed by epidermal keratinocytes in wound healing and psoriasis, conditions that are characterized by increased microvascular permeability and angiogenesi”
BackgroundVascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis
Dor, Y., Porat, R., & Keshet, E. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.280.6.c1367 · Cited by 237
Lymphatic endothelium: a new frontier of metastasis research
Karkkainen, M. J., Mäkinen, T., & Alitalo, K. (2002) · Nature Cell Biology · doi:10.1038/ncb0102-e2 · Cited by 226
Lee, P., Goishi, K., Davidson, A. J., Mannix, R., Zon, L., & Klagsbrun, M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162366299 · Cited by 215
Placental growth factor is a survival factor for tumor endothelial cells and macrophages.
Adini, A., Kornaga, T., Firoozbakht, F., & Benjamin, L. E. (2002) · PubMed · Cited by 212
Fraser, H. M., Dickson, S. E., Lunn, S. F., Wulff, C., Morris, K. D., Carroll, V. A., & Bicknell, R. (2000) · Endocrinology · doi:10.1210/endo.141.3.7369 · Cited by 205 · cited 1×
“Administration of VEGF inhibitors suppresses luteal angiogenesi”
Preclinical Safety Evaluation of rhuMAbVEGF, an Antiangiogenic Humanized Monoclonal Antibody
Ryan, A. M., Eppler, D. B., Hagler, K. E., Bruner, R. H., Thomford, P. J., Hall, R. L., Shopp, G. M., & O'Neill, C. A. (1999) · Toxicologic Pathology · doi:10.1177/019262339902700115 · Cited by 202 · cited 1×
“VEGF neutralization in juvenile primates does not result in any significant abnormalities except the suppression of growth-plate and ovarian angiogenesis, as described belo”
BackgroundThe role of VEGF in normal and neoplastic hematopoiesis
Gerber, H.-P., & Ferrara, N. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0397-4 · Cited by 202 · cited 1×
“VEGF is expressed in a variety of cell lines derived from various hematologic malignancies, including multiple myeloma, T-cell lymphoma, acute lymphoblastic leukemia, Burkitt lymphoma, histiocytic lymphoma and chronic myelocytic leukemia (reviewed in ref”
BackgroundSelf-citationDavis-Smyth, T., Chen, H., Park, J., Presta, L. G., & Ferrara, N. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00872.x · Cited by 200
Self-citationFerrara, N., Frantz, G., LeCouter, J., Dillard-Telm, L., Pham, T., Draksharapu, A., Giordano, T., & Peale, F. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64322-2 · Cited by 198
Self-citationHaigh, J. J., Gerber, H.-P., Ferrara, N., & Wagner, E. F. (2000) · Development · doi:10.1242/dev.127.7.1445 · Cited by 192
Self-citationGille, H., Kowalski, J., Yu, L., Chen, H., Pisabarro, M. T., Davis-Smyth, T., & Ferrara, N. (2000) · The EMBO Journal · doi:10.1093/emboj/19.15.4064 · Cited by 181
Self-citationSmolich, B. D., Yuen, H. A., West, K. A., Giles, F. J., Albitar, M., & Cherrington, J. M. (2001) · Blood · doi:10.1182/blood.v97.5.1413 · Cited by 180
Bates, D. O., & CURRY, F. E. (1997) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1997.273.2.h687 · Cited by 149
Kim, H., Barroso, M., Samanta, R., Greenberger, L., & Sztul, E. (1997) · American Journal of Physiology · doi:10.1152/ajpcell.1997.273.2.c687 · Cited by 122
LeCouter, J. E., Lin, R., & Ferrara, N. (2002) · Nature Medicine · doi:10.1038/nm0902-913 · Cited by 119 · cited 1×
“EG-VEGF is not structurally related to VEGF, but belongs to a unique gene famil”
BackgroundSelf-citationZimmermann, R. C., Xiao, E., Husami, N., Sauer, M. V., Løbo, R. A., Kitajewski, J., & Ferin, M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7181 · Cited by 117
Mole, D. R., Maxwell, P. H., Pugh, C. W., & Ratcliffe, P. J. (2001) · IUBMB Life · doi:10.1080/15216540252774757 · Cited by 117 · cited 1×
“Recent studies have uncovered the crucial role of the product of the von Hippel–Lindau (VHL) tumor suppressor gene in HIF-1-dependent hypoxic responses (reviewed in ref”
BackgroundMyeloid progenitor cell regulatory effects of vascular endothelial cell growth factor.
Broxmeyer (1995) · International Journal of Hematology · doi:10.1016/0925-5710(95)00412-2 · Cited by 112
Belandia, B., Latasa, M. J., Villa, A., & Pascual, A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30366 · Cited by 112
(1999) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789812815132_0019 · Cited by 109
Rosenberg, C. L., Motokura, T., Kronenberg, H. M., & Arnold, A. (1993) · PubMed · Cited by 107
Zimmermann, R. C. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.2.768 · Cited by 71
Maru, Y., Yamaguchi, S., & Shibuya, M. (1998) · Oncogene · doi:10.1038/sj.onc.1201786 · Cited by 57
Pathobiology of Ocular Disease
Katz, B. (1995) · Journal of Neuro-Ophthalmology · doi:10.1097/00041327-199506000-00016 · Cited by 53
Polycystic ovary syndrome/hyperandrogenic chronic anovulation.
Ra, L. (1995) · PubMed · Cited by 39
Research works printed but not linked: 3
- Presta, L.G. et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593–4599 (1997).
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
- Yang, J.C. et al. A randomized trial of bevacizumab (anti-VEGF antibody) in metastatic renal cancer. N. Engl. J. Med. (in the press).
Cited by
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Self-citationMolecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Angiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Self-citation
Metadata
- Authors
- Ferrara, N., Gerber, H.-P., & LeCouter, J.
- Affiliations
- Genentech (US)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature Medicine
- Published
- 2003-06-01
- Volume
- 9
- Issue
- 6
- Pages
- 669-676
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2000292756
- Cited by
- 9,591
- References
- 144
- Citations by year
- 2026: 154 · 2025: 270 · 2024: 292 · 2023: 317 · 2022: 336 · 2021: 386 · 2020: 379 · 2019: 403 · 2018: 384 · 2017: 466 · 2016: 460 · 2015: 485 · 2014: 551 · 2013: 527 · 2012: 580
- FWCI
- 28.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- vascular endothelial growth factor, VEGF receptors, VEGFR1, VEGFR2, receptor tyrosine kinase signaling, angiogenesis, pathological angiogenesis, tumor angiogenesis, intraocular neovascularization, VEGF inhibitors, age-related macular degeneration, vascular leakage, embryonic development
- MeSH terms
- Animals, Clinical Trials as Topic, Endothelium, Vascular, Growth Substances, Humans, Lymphokines, Neovascularization, Pathologic, Oxygen, Signal Transduction, Endothelial Growth Factors, Neovascularization, Physiologic, Protein Isoforms, Intercellular Signaling Peptides and Proteins, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.